AMH rs17585: Genetic Variation and Ovarian Physiology
The rs17585 variant is a common missense change (c.146G>T, p.Ile49Ser) located within the AMH gene on chromosome 19. It alters an amino acid in the prodomain of anti-Müllerian hormone, a key signaling factor produced by ovarian granulosa cells. Research has investigated its potential role in modulating hormone bioactivity, follicular recruitment, and reproductive traits, though overall clinical associations remain modest and mixed.
What each genotype means
Typical AMH bioactivity
You carry two copies of the common C allele (encoding Ile49), representing baseline anti-Müllerian hormone protein function. Studies indicate typical circulating AMH bioactivity and expected baseline follicular dynamics, though reproductive measures are influenced by many complex factors. This genotype is generally considered the reference baseline across fertility and ovarian reserve studies.
Carried by approximately 60% to 65% of individuals of European ancestry and roughly 40% to 50% of individuals of East Asian ancestry.
Intermediate AMH bioactivity
You carry one copy of the missense T allele (p.Ile49Ser) and one copy of the common C allele. Some studies have linked this altered form to modestly modified AMH bioactivity or variation in follicular recruitment, while others report negligible clinical impact. Overall evidence regarding its clinical influence on ovarian response and natural fertility remains limited and mixed.
Carried by approximately 30% to 35% of individuals of European descent and about 40% to 45% of individuals of East Asian descent.
Altered AMH bioactivity
You carry two copies of the alternative T allele (encoding Ser49), which produces an AMH protein variant with altered receptor-binding properties. Certain research suggests this genotype may associate with altered circulating bioactivity and follicular recruitment, although clinical studies show mixed and inconclusive results regarding actual fertility outcomes. Anyone evaluating reproductive health or undergoing ovarian stimulation should consult their reproductive endocrinologist or clinical team.
Carried by approximately 4% of individuals of European ancestry and around 10% to 15% of individuals of East Asian ancestry.
Molecular Profile: What is rs17585?
The single nucleotide polymorphism rs17585 is a coding missense variation located on chromosome 19 in the AMH (anti-Müllerian hormone) gene. Specifically, it involves a nucleotide substitution typically reported as c.146G>T, resulting in the replacement of the amino acid isoleucine with serine at codon 49 (p.Ile49Ser). This alteration is situated within the AMH prodomain, a region that undergoes proteolytic cleavage but remains non-covalently associated with the mature signaling domain to facilitate proper folding and biological activity. Because the prodomain assists in receptor engagement and protein stability, researchers have scrutinized p.Ile49Ser for its capacity to modify downstream signaling efficiency in target tissues.
Biological Role of the AMH Gene
The AMH gene encodes anti-Müllerian hormone, a dimeric glycoprotein member of the transforming growth factor-beta (TGF-beta) superfamily. During male embryonic development, AMH produced by Sertoli cells triggers the regression of Müllerian ducts, preventing the formation of female internal reproductive structures. In females, AMH is primarily secreted by the granulosa cells of preantral and small antral follicles in the ovaries. Throughout reproductive life, AMH functions as a critical gatekeeper of ovarian physiology: it curbs excessive primordial follicle recruitment and dampens follicle sensitivity to follicle-stimulating hormone (FSH). Circulating blood concentrations of AMH serve as a clinical proxy for ovarian reserve.
Scientific Evidence and Reproductive Associations
Early in vitro and association studies suggested that the rs17585 variant might alter AMH bioactivity, potentially shifting follicular responsiveness and circulating hormone levels. Subsequent reproductive investigations explored whether carriage of the minor allele affects ovarian response during controlled ovarian stimulation protocols, in vitro fertilization (IVF) success rates, or susceptibility to polycystic ovary syndrome (PCOS). However, findings across cohorts have been inconsistent. Several prospective clinical studies evaluating women undergoing IVF have observed no statistically significant differences across rs17585 genotypes regarding oocyte retrieval numbers, total gonadotrophin requirements, or live birth rates. Consequently, current scientific evidence connecting rs17585 to altered fertility outcomes is classified as limited.
Population Distribution and Ancestry Patterns
The rs17585 polymorphism is relatively common across global populations, in sharp contrast to rare, highly penetrant pathogenic mutations in the AMH gene that cause disorders such as persistent Müllerian duct syndrome. Population genetic databases indicate noticeable differences in allele frequencies across ancestral groups. The minor allele frequency hovers around 20% in populations of European ancestry, whereas it is considerably more prevalent in East Asian populations, frequently reaching frequencies of approximately 35%. Because of these underlying demographic differences, researchers must carefully account for population stratification when assessing potential links between rs17585 and reproductive parameters.
Clinical Perspective: What This Result Means
Genotype results for rs17585 provide population-level biological insights rather than individualized clinical forecasts. The variant does not diagnose infertility, polycystic ovary syndrome, or premature ovarian insufficiency, nor does it guarantee specific outcomes during fertility treatments. Routine reproductive evaluation relies on direct physiological biomarkers, including standardized serum AMH laboratory measurements and transvaginal ultrasound antral follicle counts, alongside comprehensive clinical histories. Anyone undergoing fertility treatment or exploring reproductive health should interpret personal genetic data in consultation with a reproductive endocrinologist, genetic counselor, or specialized clinician.
How common is this variant?
The rs17585 minor allele occurs at an estimated frequency of approximately 20% in European populations and reaches approximately 35% in East Asian populations, demonstrating common worldwide distribution.
Frequently asked questions
Does having the rs17585 variant cause infertility?
No, having the rs17585 variant does not cause infertility. It is a common benign genetic variation found in significant portions of healthy populations worldwide and has not been established as a causal factor for reproductive failure.
Can rs17585 replace a serum AMH blood test?
No, genetic testing for rs17585 cannot substitute for a serum AMH test. Blood tests measure the real-time concentration of circulating hormone produced by growing follicles, which provides actionable clinical information that genotype alone cannot deliver.
How does rs17585 impact IVF outcomes?
Published clinical studies investigating women undergoing IVF have generally reported no significant differences in egg retrieval numbers, gonadotrophin requirements, or live birth rates across rs17585 genotypes. The clinical impact of the variant on IVF remains unproven.
Is rs17585 linked to polycystic ovary syndrome (PCOS)?
While researchers have evaluated rs17585 as a candidate modifier in PCOS due to AMH's role in follicular arrest, scientific evidence remains mixed. Large-scale genetic associations have not confirmed a strong or definitive causal role for this specific common polymorphism.
Sources & further reading
Educational information only, last refreshed 9/11/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs17585?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in AMH
Polymorphism in the anti-Müllerian hormone (AMH) locus associated with variation in ovarian reserve markers and follicular recruitment rates.
Loss-of-function AMH mutation precluding regression of female internal reproductive structures in 46,XY males.
Missense mutation in anti-Müllerian hormone resulting in impaired AMH signaling and persistent Müllerian duct syndrome type 1.